Clinical Trial Update: SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study is evaluating SBRT with camrelizumab and apatinib as conversion therapy for unresectable hepatocellular carcinoma; the trial status is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Unresectable Hepatocellular Carcinoma (HCC) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING